Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HU-045 vs Xeomin for Moderate to Severe Glabellar Lines
NCT06205797Phase 3Recruiting
- Sponsor
- Huons Biopharma
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of HU-045 in glabellar lines, sponsored by Huons Biopharma. Started Jun 2024; status: recruiting.
02
Drugs
HU-045
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06205797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205797.